New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 15, 2014
08:06 EDTMYL, GSKProsonix, Mylan enter licensing deal for generic version of Flixotide, Flovent
Prosonix announced that it has entered into a global licensing agreement with Mylan (MYL) for its leading inhaled respiratory products, PSX1001 and PSX1050. PSX1001 and PSX1050 are being developed as generic versions to GlaxoSmithKline's (GSK) pressurised metered dose inhalers Flixotide and Flovent, respectively. According to IMS Health, Flixotide and Flovent had global brand sales of approximately $1.3B for the 12 months ending Dec. 31, 2013. A first marketing authorisation application for PSX1001 is expected to be submitted in the European Union in 2014.
News For MYL;GSK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 1, 2015
07:46 EDTGSKFDA and the Parental Drug Association to co-host a conference
Subscribe for More Information
06:07 EDTGSKGSK enters development agreement, R&D collaboration with Propeller Health
Propeller Health announced a development agreement and R&D collaboration with GSK for its Ellipta inhaler, the pharmaceutical company's innovative, patented, dry powder inhaler. Under the terms of this non-exclusive agreement, the first between the two companies, Propeller Health will develop and manufacture a custom sensor for the Ellipta inhaler for use in certain GSK clinical studies in asthma and COPD.
November 27, 2015
08:00 EDTGSKGlaxo has cut 40% of China sales reps in wake of scandal, Reuters reports
Subscribe for More Information
07:34 EDTGSKGlaxoSmithKline starts phase III study of sirukumab in Giant Cell Arteritis
Subscribe for More Information
November 25, 2015
11:29 EDTGSKStudy says Valeant, others exploding dermatology drug prices, WSJ reports
The JAMA Dermatology journal published a new study that found that retail prices of 19 dermatologic prescription drugs increased fivefold on average between 2009 and 2015, reported The Wall Street Journal. Targretin, marketed by Valeant (VRX), jumped to $30,320 this year from $15,708 last year and $1,687 in 2009, the study found, but "It's not just Valeant," said lead author Miranda Rosenberg. Prices for drugs made by GlaxoSmithKline (GSK) and Novartis (NVS) at least doubled or tripled over the same time frame, the report noted. Reference Link
06:04 EDTMYLMylan and Perrigo set to face-off over potential targets, Bloomberg reports
Mylan (MYL) will likely find itself now competing with Perrigo (PRGO) for other assets, reports Bloomberg. According to Bloomberg Intelligence analyst Elizabeth Krutoholow, both companies may look to buy Impax Laboratories (IPXL), Stada Arzneimittel or Taro Pharmaceutical Industries (TARO). All of the potential targets are attractive due to their over-the-counter products. Reference Link
November 24, 2015
11:16 EDTGSKAdaptimmune initiates Phase I/II trial of affinity enhanced T-cell therapy
Subscribe for More Information
07:33 EDTMYLMylan launches Clozapine Orally Disintegrating Tablets in the U.S.
Mylan (MYL) announced the U.S. launch of Clozapine Orally Disintegrating Tablets, 25 mg and 100 mg, the generic version of Jazz Pharmaceutical's FazaClo (JAZZ). Mylan received final approval from the FDA for its Abbreviated New Drug Application, or ANDA, for this product, which is used for the treatment of severely ill patients with schizophrenia who fail to respond adequately to standard antipsychotic treatment.
November 23, 2015
08:08 EDTGSKIdera Pharmaceuticals announces partnership with GSK
Idera Pharmaceuticals (IDRA) announced it has entered into an exclusive worldwide collaboration and license agreement with GSK (GSK) to research, develop and commercialize selected molecules from Idera's 3rd generation antisense platform for the treatment of selected targets in renal disease. Under the terms of the agreement, Idera is eligible to receive approximately $100M in development and regulatory milestone payments, including a $2.5M upfront payment. Additionally, Idera is eligible to receive royalties on all sales upon commercialization at varying rates up to five percent on annual net sales in excess of $500M.
November 20, 2015
07:32 EDTMYLMylan completes acquisition of certain businesses from Famy Care
Subscribe for More Information
November 19, 2015
15:29 EDTMYLMylan confirms first-to-file patent challenge relating to Delzicol
Subscribe for More Information
13:52 EDTMYLMylan announces U.S. launch of generic Adderall tablets
Subscribe for More Information
November 18, 2015
08:22 EDTMYLMylan resinstated with an Overweight at JPMorgan
Subscribe for More Information
08:11 EDTGSKIMS Health forecasts global drug spending to increase 30% by 2020 to $1.4T
Subscribe for More Information
06:02 EDTMYLPerrigo upgraded to Buy from Neutral at B. Riley
Subscribe for More Information
November 17, 2015
10:11 EDTMYLOptions with decreasing implied volatility
Subscribe for More Information
07:34 EDTMYLMylan launches Almotriptan Tablets USP in the U.S.
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use